M&A / Deals MSD-backed Ray locks in $125m to back eye drug pipeline Pharmaceutical TechnologyRay's MSD and Novo Holdings-backed Series B will shed light on the potential of the company's vision restoration gene therapy pipeline.M&A / DealsOphthalmologyRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaceutical Technology Ray’s MSD and Novo Holdings-backed Series B will shed light on the potential of the company’s vision restoration gene therapy pipeline. M&A / DealsOphthalmologyRead full story Post navigation Previous: New data build case for Roche’s oral BTK drug for MSNext: FDA delays decision on Sanofi’s subcutaneous Sarclisa Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
